In the last trading session, 1.17 million ProQR Therapeutics N.V (NASDAQ:PRQR) shares changed hands as the company’s beta touched 0.36. With the company’s per share price at $1.63 changed hands at $0.09 or 5.84% during last session, the market valuation stood at $171.50M. PRQR’s last price was a discount, traded about -183.44% off its 52-week high of $4.62. The share price had its 52-week low at $1.07, which suggests the last value was 34.36% up since then. When we look at ProQR Therapeutics N.V’s average trading volume, we note the 10-day average is 0.65 million shares, with the 3-month average coming to 532.33K.
Analysts gave the ProQR Therapeutics N.V (PRQR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended PRQR as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. ProQR Therapeutics N.V’s EPS for the current quarter is expected to be -0.16.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Instantly PRQR was in green as seen at the end of in last trading. With action 20.74%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -38.49%, with the 5-day performance at 20.74% in the green. However, in the 30-day time frame, ProQR Therapeutics N.V (NASDAQ:PRQR) is 16.43% up. Looking at the short shares, we see there were 0.83 million shares sold at short interest cover period of 1.12 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.75, meaning bulls need an upside of 56.53% from its current market value. According to analyst projections, PRQR’s forecast low is 2 with 5 as the target high. To hit the forecast high, the stock’s price needs a -206.75% plunge from its current level, while the stock would need to soar -22.7% for it to hit the projected low.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Year-over-year growth is forecast to reach -8.74% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 4.95M. 7 analysts are of the opinion that ProQR Therapeutics N.V’s revenue for the current quarter will be 4.87M. The company’s revenue for the corresponding quarters a year ago was 5.02M and 7.05M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -1.35%. The estimates for the next quarter sales put growth at -30.91%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 25.70%. The 2025 estimates are for ProQR Therapeutics N.V earnings to decrease by -27.19%, but the outlook for the next 5-year period is at -19.10% per year.
PRQR Dividends
ProQR Therapeutics N.V is expected to release its next quarterly earnings report on 2025-Mar-12.
ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.06% of ProQR Therapeutics N.V shares while 53.90% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 65.79%. There are 53.90% institutions holding the ProQR Therapeutics N.V stock share, with PRIVIUM FUND MANAGEMENT B.V. the top institutional holder. As of 2024-06-30, the company held 6.8336% of the shares, roughly 5.58 million PRQR shares worth $9.21 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 4.4394% or 3.63 million shares worth $6.02 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Delaware Group Equity Funds IV-Macquarie Healthcare Fund and Meridian Fund Inc-Meridian Small Cap Growth Fund . With 620.0 shares estimated at $1.01 million under it, the former controlled 0.59% of total outstanding shares. On the other hand, Meridian Fund Inc-Meridian Small Cap Growth Fund held about 0.49% of the shares, roughly 520.25 shares worth around $0.85 million.
